Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Study of Derazantinib in Patients With Inoperable or Advanced Intrahepatic Cholangiocarcinoma and FGFR2 Gene Fusions or FGFR2 Gene Mutations or Amplifications

NCT03230318 is registered in ClinicalTrials.gov with Basilea Pharmaceutica as lead sponsor.

NCT NCT03230318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03230318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Study of Derazantinib in Patients With Inoperable or Advanced Intrahepatic Cholangiocarcinoma and FGFR2 Gene Fusions or FGFR2 Gene Mutations or Amplifications
Lead sponsor
Basilea Pharmaceutica
Phase
Phase 2
Overall status
Completed
Start date
September 28, 2017
Completion date
October 25, 2022
Enrollment
148 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

combined hepatocellular and cholangiocarcinoma, intrahepatic cholangiocarcinoma